Replies to post #8754 on CytoSorbents Corporation (CTSO)

[Babykahn]

It's a bust because Chan misplayed his hand.

Let's review....
I recall a quarterly conf call last August where Chan hinted how encouraging the data was and we would see it in Oct. Then when it wasn't disclosed, he had to explain that it would come at a later date because of discussions with the FDA on REFRESH 2 and then even later the excuse was he was not going to release it because he didn't want the perception that CTSO was hyping the results. So we waited until the May 2017 conference in Boston, and what does Chan do - he bungles it again by not press releasing the data the day of the presentation. So shareholders email him and beg for a press release that comes out days later. Then in the Q1 2017 conference call, he drones on for 15 minutes about REFRESH 1. And then we learn we still don't have an end point for REFRESH 2. And AKI as an endpoint scares the poop out of me.

I'm dizzy just typing this convoluted story.


I'm long in the stock since the old ticker symbol and own way too many shares. I wish we had a more aggressive business development oriented CEO.

[orangecat]

Hmmm. I didn't pick up on it before, because I was listening to the Q1 call in my car and did not see the slides. The REFRESH 1 study treatment group patients were treated with dual Cytosorb cartridges. So, double any calculations of potential Cytosorb sales for complex cardiac surgery.